Neumora Therapeutics is trading at $0.49, down 6.70%, with no verified company-specific announcement or catalyst explaining the decline on October 6, 2026. - Available search surfaced Neumora’s indexed Phase 3 announcement, but it is an older release, not a new event. - The Nasdaq rose 0.57% and the S&P 500 gained 0.50%; Neumora’s decline does not appear to track the positive broad-market direction. No clear cause is established.